These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The development of immunotherapy in older adults: New treatments, new toxicities? Helissey C; Vicier C; Champiat S J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796 [TBL] [Abstract][Full Text] [Related]
9. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Nagai H; Muto M Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216 [TBL] [Abstract][Full Text] [Related]
10. [Toxicities of immune checkpoint inhibitors and their management]. Kostine M; Marabelle A; Schaeverbeke T; Kfoury M Med Sci (Paris); 2019 Dec; 35(12):949-956. PubMed ID: 31903899 [TBL] [Abstract][Full Text] [Related]
11. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Kottschade LA Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902 [TBL] [Abstract][Full Text] [Related]
12. [Toxicity of immune checkpoints inhibitors]. Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624 [TBL] [Abstract][Full Text] [Related]
13. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182 [TBL] [Abstract][Full Text] [Related]
14. [Immune-related adverse events of checkpoint inhibitors: an internist/general practitioner's point of view]. Cisarovsky C; Kraege V; Obeid M; Garnier A Rev Med Suisse; 2020 Nov; 16(716):2264-2270. PubMed ID: 33237644 [TBL] [Abstract][Full Text] [Related]
15. Supportive care for patients undergoing immunotherapy. Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167 [TBL] [Abstract][Full Text] [Related]
16. Part 1: Imaging findings of common immune checkpoint inhibitor-related adverse effects. Noë G; Cardin A; Lasocki A J Med Imaging Radiat Oncol; 2022 Jun; 66(4):495-501. PubMed ID: 35244329 [TBL] [Abstract][Full Text] [Related]
17. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events. Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240 [TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Roberts K; Culleton V; Lwin Z; O'Byrne K; Hughes BG Asia Pac J Clin Oncol; 2017 Aug; 13(4):277-288. PubMed ID: 28699304 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Gill D; Hahn AW; Sonpavde G; Agarwal N Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of hospitalizations among patients receiving immune checkpoint inhibitors at a community teaching hospital. Rasor B; Henderson R; Chan K J Oncol Pharm Pract; 2020 Jan; 26(1):60-66. PubMed ID: 30924739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]